Drug Data Sends ImmunoGen (NASDAQ: IMGN) To Multi-Year Highs, Up 150% In Two Days

Shares of biotech firm ImmunoGen IMGN are surging for a second straight day after the company reported positive ovarian cancer drug data on Wednesday. At last check, the stock was up nearly 11% to $13.56 on very elevated volume. In the wake of Thursday’s aggressive breakout continuation, IMGN is now trading above levels last seen back in 2018.

The stock has now surged more than 150% in the last two days as Wall Street is clearly excited about the prospects of the firm’s MIRASOL treatment after phase 3 data showed statistically significant results compared to chemotherapy in ovarian cancer patients who have received therapy.

MIRASOL showed a 33% reduction in death risk in the trial.

After more than doubling on this news, IMGN currently has a market cap of just over $3 billion. The technical outlook here is extremely positive, although a snap-back move in the coming days is possible due to the extended move in the name.

Featured photo by National Cancer Institute on Unsplash.

Market News and Data brought to you by Benzinga APIs